ABT Stock Recent News

Abbott (ABT) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $0.98 per share a year ago.

Abbott stock slipped early Wednesday after the health giant reported light first-quarter sales, though profit beat expectations.

Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments.

Abbott Labs posts first-quarter adjusted profit that topped analysts' estimates.

Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices.

First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increase ABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2025.

Abbott Laboratories ABT will release its first-quarter earnings results before the opening bell on Wednesday, April 16.

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.